Clinical Scorecard: Cardiovascular Benefits of Incretin-Based Therapies Beyond Diabetes: Insights into Mechanisms and Future Therapeutic Approaches from GLP-1 Receptor Agonists to Multi-Agonist Strategies
At a Glance
Category
Detail
Condition
Cardiovascular disease in patients with type 2 diabetes and other conditions
Patients with type 2 diabetes, obesity, chronic kidney disease, heart failure with preserved ejection fraction, and peripheral artery disease.
Care Setting
Cardiometabolic medicine
Key Highlights
GLP-1 receptor agonists reduce major adverse cardiovascular events in high-risk patients.
Semaglutide has shown cardiovascular benefits in patients with obesity and established cardiovascular disease without diabetes.
Combination therapies with SGLT2 inhibitors and other agents are evolving treatment strategies.
Guideline-Based Recommendations
Diagnosis
Assess cardiovascular risk in patients with type 2 diabetes and other relevant conditions.
Management
Prioritize GLP-1 receptor agonists with proven cardiovascular outcomes in appropriate patient populations.
Monitoring & Follow-up
Evaluate cardiovascular outcomes and adjust treatment based on individual patient response.
Risks
Consider variability in treatment effects based on molecule, dose, and patient characteristics.
Patient & Prescribing Data
Individuals with type 2 diabetes, obesity, chronic kidney disease, heart failure with preserved ejection fraction, and symptomatic peripheral artery disease.
Efficacy varies by agent and requires careful selection based on clinical trial data.
Clinical Best Practices
Utilize cardiovascular outcome trials to guide treatment decisions.
Monitor for weight-independent mechanisms of action in incretin therapies.
